The Association for the Advancement of Medical Instrumentation (AAMI) is reporting that the Food and Drug Administration (FDA) has issued updated guidance on the regulatory requirements for gowns used in healthcare settings. The FDA has long regulated gowns used during surgical procedures, but there has been some confusion in the industry over whether other types of gowns fall under the agency’s regulatory purview. The new FDA guidance was intended to help clarify the characteristics of gowns considered to be Class II devices and therefore subject to premarket scrutiny. However, the agency specifically stated that the guidance would “not resolve existing differences in terminology.”
“Since the original 1988 final rule, a number of terms have been used to refer to gowns intended for use in healthcare settings including, but not limited to, surgical gowns, isolation gowns, surgical isolation gowns, nonsurgical gowns, cover gowns, comfort gowns, procedural gowns and operating room gowns,” the FDA stated as background in its guidance document.
According to the agency, it considers both level-of-protection claims and descriptive terminology when determining whether a particular type of gown should be classified as a Class I or Class II medical device. The classification generally correlates to risk level, with Class I comprising devices that pose the lowest risk to patients and users, and Class II reserved for devices that pose a moderate risk. For manufacturers, the classifications are important because they directly relate to the amount of regulatory scrutiny any given device faces-the higher the risk level, the greater the scrutiny.
Based on the new guidance, gowns claiming to provide ANSI/AAMI PB70 Level 3 or 4 protection, which corresponds to moderate or high-level barrier protection, are considered to be Class II medical devices and must demonstrate the liquid barrier performance defined within the PB70 standard. In addition, any gown labeled as a “surgical gown” or one “intended for use during sterile procedures” also falls into this category.
Class II gowns are subject to FDA review, and the 510(k) submission should contain the following information in addition to the items identified in the FDA’s 1993 Guidance on Premarket Notification [510(k)] Submissions for Surgical Gowns and Surgical Drapes: Evidence that the gown complies with the claimed barrier performance criteria of the currently FDA-recognized version of ANSI/AAMI PB70 or equivalent standard. ANSI/AAMI PB70 establishes barrier performance and documentation requirements for gowns and their materials. Performance test data to demonstrate that the gown is an effective barrier in accordance with ANSI/AAMI PB70 barrier performance specifications. For both single use and reusable gowns, barrier performance testing should be completed on the final, finished, pre-shipment gown, at the end of the stated shelf life of the gown. If the gown is intended to be reusable, barrier performance testing should also be performed at the end of the labeled use-life (maximum reprocessing cycles). Representative engineering drawing(s), schematics, illustrations, and/or figures of the gown that are clear, legible, labeled with the barrier protection levels of the gown, and include dimensions and the location of the critical and non-critical zones. Sample labeling that clearly identifies the level of liquid barrier protection per ANSI/AAMI PB70. Sample labeling that includes the direction(s) for use and indication(s) for use. Although this guidance is intended to clarify the FDA’s current thinking on the topic, there is lingering concern in the industry about variations in terminology.
“The FDA has tried to clarify when it is necessary to file a 510(k) application for protective attire and drapes. Unfortunately, to do this it has created a new term-surgical isolation gown,” says Donna Swenson, president and CEO of Sterile Processing Quality Services, Inc. and co-chair of AAMI’s Protective Barriers Committee. “The PB70 committee generally understands that protective attire and drapes that provide a higher level of protection (AAMI Level 3 or 4) require more controls in the manufacturing process, including a requirement for these products to have an approved 510(k). However, using the term ‘surgical isolation gown’ could cause more confusion instead of clarifying the issue.”
Source: AAMI
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.